Abstracts tagged "Patient reported outcomes"

Abstract Number: 0127 • ACR Convergence 2022
The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function
Aleksander Lenert¹, Robyn Domsic², Karmela Kim Chan³, Melissa Oliver⁴, Jisna Paul⁵, Courtney Kremer⁶, Emma Leisinger¹, Svjetlana Dolovcak⁷, Sandy D. Hong⁸, Aruni Jayatilleke⁹, Petar Lenert⁷, T. Shawn Sato¹, Samir Shah¹⁰, Shima Yasin¹¹, Yongdong (Dan) Zhao¹², Daniel Solomon¹³, Jonathan Templin¹ and Polly Ferguson¹¹, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³Hospital for Special Surgery, New York, NY, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Ohio State University Hospital, Dublin, OH, ⁶University of Iowa Stead Family Children's Hospital, Solna, IA, ⁷University of Iowa Hospitals and Clinics, Iowa City, IA, ⁸University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁹Temple University, PHILADELPHIA, PA, ¹⁰Tufts Medical Center, Boston, MA, ¹¹University of Iowa Carver College of Medicine, Iowa City, IA, ¹²University of Washington, Redmond, WA, ¹³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) and disease impact are important to adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO) but remain poorly described. Patient-reported…
Abstract Number: 0264 • ACR Convergence 2022
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Kent Kwas Huston¹, Christopher Adams², Simon Helfgott³, Jasvinder singh⁴, Nehad Soloman⁵, Dan Persons⁶, Scott Milligan⁶ and Colin Edgerton², ¹Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ²Articularis Healthcare, Sullivans Island, SC, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Trio Health, Louisville, CO
Background/Purpose: The development, exacerbation, or unimprovement of clinical conditions during DMARD treatment may lead patients to abandon treatment before the necessary time has elapsed for…
Abstract Number: 0412 • ACR Convergence 2022
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Lianne Gensler³, Jonathan Kay⁴, Victoria Navarro-Compán⁵, Christine de la Loge⁶, Alicia Ellis⁷, Carmen Fleurinck⁸, Marga Oortgiesen⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Colombes, France, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impacts patients' (pts) physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively…
Abstract Number: 0838 • ACR Convergence 2022
Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
Lisa Mandl¹, Benjamin Swett¹, Robyn Lipschultz¹, Myriam Lin¹, Alison Zhao², Carola Hanreich¹, Dongmei Sun¹, Kethy Jules-elysee¹ and Friedrich Boettner¹, ¹Hospital for Special Surgery, New York, NY, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Background/Purpose: Over 520 million people have been infected by SARS-CoV-2. In 10-40%, disabling symptoms such as fatigue and dyspnea can persist. Risk factors for poor…
Abstract Number: 1272 • ACR Convergence 2022
Application of the Consolidated Framework for Implementation Research (CFIR) to Study Top-Performing Practices in the RISE Registry
Lindsay Jacobsohn¹, Catherine Nasrallah², Cammie Young³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Collection and use of rheumatoid arthritis (RA) disease activity and functional status outcome measures facilitates treating-to-target and shared decision-making. Although guidelines recommend regular use…
Abstract Number: 1392 • ACR Convergence 2022
Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
Maria Mirza¹, Kaiyang Song¹, Madiha Ashraf², Anushka Soni³, John Jackman³ and Raashid Luqmani¹, ¹Oxford University Hospital, Oxford, United Kingdom, ²Oxford Universtiy Hospital, Oxford, United Kingdom, ³Oxford University Hospital, Oxford, England, United Kingdom
Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…
Abstract Number: 1927 • ACR Convergence 2022
Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults
Rebecca Overbury¹, Devin Eddington², Katherine Sward², John Bohnsack¹, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City
Background/Purpose: The Adult Center for Childhood Onset Rheumatic Disease (ACCORD) is a clinical and research center for the health care transition (HCT) of adolescent and…
Abstract Number: 2170 • ACR Convergence 2022
Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
Francesco Del Galdo¹, Suiyuan Huang², Lesley-Anne Bissell³, sindhu johnson⁴, Daniel Furst⁵ and Dinesh Khanna⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ²University of Michigan, Ann Arbor, MI, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
Abstract Number: 0093 • ACR Convergence 2021
The Association of General and Covid-19-Specific Stress with Changes in Patient-Reported Outcomes and Comorbidities
Patricia Katz¹, Kristin Wipfler², Sofia Pedro³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: We previously showed that perceived stress during the COVID-19 pandemic was associated with concomitant increases in symptoms of depression and anxiety. In lupus alone,…
Abstract Number: 0367 • ACR Convergence 2021
Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Souzi Makri², Denis Poddubnyy³, Christine Bundy⁴, Laura Christen⁵, Sergio Sanz-Gomez⁶, José Correa-Fernández⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Victoria Navarro-Compán⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ³Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁴Cardiff University, Cardiff, Wales, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: Patient organizations (POs) provide education and support services aimed to improve the quality of life of axSpA patients. This analysis aims to identify factors…
Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Weiheng Chen¹, Mengge Song¹, Yan Jia¹, Jigao Sun¹, Yan Zhao², Zhipeng Xue³, Qianglong Chen², xiangrong Zeng² and Chenchen Wang⁴, ¹The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), ²2Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), ³1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
Abstract Number: 0761 • ACR Convergence 2021
Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome
Briana Ndife¹, Sheri Fenel², Sandy Lewis² and Neetu Agashivala³, ¹Novartis, East Hanover, NJ, ²RTI Health Solutions, Research Triangle Park, NC, ³Novartis Pharmaceutical Corporation, East Hanover, NJ
Background/Purpose: Sjögren’s Syndrome (SS) is a systemic autoimmune disease associated with a wide range of symptoms and long-term complications. While clinical indices are useful in…
Abstract Number: 0853 • ACR Convergence 2021
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Craig Willers¹, Tom Lynch¹, Vibhasha Chand², Mohammad Islam³, Marissa Lassere⁴, Helen Keen⁵, Tony Kenna⁶, Susan Lester⁷, Ranjeny Thomas⁸, Premarani Sinnathurai⁹, Mihir Wechalekar¹⁰, Ashley Fletcher¹¹, Daniel Lightowler¹², Sheeraz Mohd¹³, Nishta Ramnoruth¹⁴, Carlee Ruediger¹⁵, Helen Weedon¹⁶ and Lyn March¹⁷, ¹Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, ²Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Information and Communications Technology, University of Sydney, Sydney, Australia, ⁴St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁵University of Western Australia, Daglish, Australia, ⁶Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁷Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁸University of Queensland, Diamantina Institute, Brisbane, Australia, ⁹Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ¹⁰Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, ¹¹Cabrini Health, Malvern, Australia, ¹²Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, ¹³Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, ¹⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ¹⁵University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁶Flinders University, Bedford Park, Australia, ¹⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia
Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
Abstract Number: 1213 • ACR Convergence 2021
Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
Christoph Baerwald¹, Edgar Stemmler², Sixten Gnuechtel², Katharina Birkner², Carsten Holland³, Bjoern Fritz², Daniela Adolf⁴ and Ralf Baron⁵, ¹University Hospital Leipzig, Leipzig, Germany, ²AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ³AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁴StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁵University Hospital Schleswig-Holstein, Kiel, Germany
Background/Purpose: Pain is the symptom with the most significant impact on patients’ lives in rheumatoid arthritis (RA), whereas 17% of German RA patients report severe…
Abstract Number: 1334 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Gender disparities in PsA can affect natural course of disease, clinical presentation and response to medication1. The German non-interventional study AQUILA provides real-world data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].